MIRA Pharmaceuticals (MIRA) said Friday that preclinical data showed its oral ketamine analog Ketamir-2 achieved a "complete reversal of neuropathic pain in preclinical models."
In preclinical studies, Ketamir-2 showed "superior efficacy" compared with ketamine, the company said, adding that it is on track to submit an investigational new drug application to the US Food and Drug Administration by December.
MIRA Pharmaceuticals said it plans to show an efficacy signal in humans in 2025.
Shares of the company were up 2.8% in recent premarket activity.
Price: 1.1000, Change: +0.03, Percent Change: +2.80
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。